Logo do repositório

Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats

dc.contributor.authorde Souza, Aline
dc.contributor.authorScarim, Cauê Benito [UNESP]
dc.contributor.authorCotrim, Paulo Cesar
dc.contributor.authorJunior, Fernando Barbosa
dc.contributor.authorRocha, Bruno Alves
dc.contributor.authorCalixto, Leandro Augusto
dc.contributor.authorCorreia, Cristiano Jesus
dc.contributor.authorde Barros Araújo, Gabriel Lima
dc.contributor.authorLöbenberg, Raimar
dc.contributor.authorBou-Chacra, Nádia Araci
dc.contributor.authorBreithaupt-Faloppa, Ana Cristina
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionFaculty of Pharmacy & Pharmaceutical Sciences
dc.date.accessioned2025-04-29T19:34:08Z
dc.date.issued2024-02-01
dc.description.abstractBackground: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.en
dc.description.affiliationFaculty of Pharmaceutical Sciences University of São Paulo, SP
dc.description.affiliationDepartment of Drugs & Medicines School of Pharmaceutical Sciences São Paulo State University
dc.description.affiliationSeroepidemiology Cellular & Molecular Immunology Laboratory Institute of Tropical Medicine University of São Paulo, Dr. Enéas de Carvalho Aguiar 470, Jardim América, SP
dc.description.affiliationLaboratory of Toxicology & Essentiality of Metals Faculty of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo, SP
dc.description.affiliationFederal University of São Paulo Department of Pharmaceutical Sciences Institute of Environmental Chemical & Pharmaceutical Sciences, SP
dc.description.affiliationLaboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação (LIM-11) Instituto do Coração (InCor) Faculdade de Medicina Universidade de São Paulo
dc.description.affiliationUniversity of Alberta Faculty of Pharmacy & Pharmaceutical Sciences
dc.description.affiliationUnespDepartment of Drugs & Medicines School of Pharmaceutical Sciences São Paulo State University
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 2017/08332-3
dc.format.extent293-301
dc.identifierhttp://dx.doi.org/10.2217/nnm-2023-0263
dc.identifier.citationNanomedicine, v. 19, n. 4, p. 293-301, 2024.
dc.identifier.doi10.2217/nnm-2023-0263
dc.identifier.issn1748-6963
dc.identifier.issn1743-5889
dc.identifier.scopus2-s2.0-85186626773
dc.identifier.urihttps://hdl.handle.net/11449/304183
dc.language.isoeng
dc.relation.ispartofNanomedicine
dc.sourceScopus
dc.subjectchylomicrons
dc.subjectcycloheximide
dc.subjecthydroxymethylnitrofurazone
dc.subjectlymphatic system
dc.subjectnanostructured lipid carrier
dc.titleHydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in ratsen
dc.typeArtigopt
dspace.entity.typePublication
relation.isOrgUnitOfPublication95697b0b-8977-4af6-88d5-c29c80b5ee92
relation.isOrgUnitOfPublication.latestForDiscovery95697b0b-8977-4af6-88d5-c29c80b5ee92
unesp.author.orcid0000-0003-4307-6497[1]
unesp.author.orcid0000-0002-2540-6395[2]
unesp.author.orcid0000-0003-2607-8837[3]
unesp.author.orcid0000-0002-2498-0619[4]
unesp.author.orcid0000-0001-7893-758X[5]
unesp.author.orcid0000-0003-1776-7470[6]
unesp.author.orcid0000-0002-1690-9951[7]
unesp.author.orcid0000-0001-7590-3587[8]
unesp.author.orcid0000-0002-0919-0213[9]
unesp.author.orcid0000-0002-5271-5468[10]
unesp.author.orcid0000-0003-0554-0674[11]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos